Saturday 17 October 2026
Export OLMA’s income statement to Excel — free account
Olema Pharmaceuticals, Inc.
OLMA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 19.6%, free cash flow fell 54.3% and total debt was flat, each against the same quarter a year earlier.
6.58
0.29
−4.22%
Follow OLMA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (52.74%) | (42.86%) | (36.61%) | (59.22%) |
+8 more TTM periods Free account |
|
| (47.10%) | (39.38%) | (33.00%) | (51.48%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(49.07%) | (39.73%) | (35.04%) | (51.24%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.58) | (1.45) | (1.69) | (1.57) | |
Free Cash Flow |
(164.96) | (148.72) | (146.72) | (134.67) | |
Capital Expenditures |
(0.23) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(18.44%) | (15.04%) | (14.86%) | (21.06%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.81 | 0.80 | 0.90 | 0.90 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.50) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.58) | (1.45) | (1.69) | (1.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates